GlobalLogic, a Hitachi Group Company, and digital engineering specialist have been selected by Inspira Technologies to develop an algorithm-based platform that will empower ART device – an Early Extracorporeal Respiratory Support system targeting respiratory failure patients such as those diagnosed with COVID-19.
Inspira Technologies created the ART that allows the management of the population of patients whose condition keeps deteriorating after non-invasive ventilation. Currently, after non-invasive ventilation, the only treatment available to them is highly invasive mechanical ventilation. The ART device makes use of a haemo protective flow approach that allows oxygen saturation level rebalanced while patients are awake and breathing spontaneously possibly reducing the need for mechanical ventilation. The ART is designed in a way that will allow enrichment of 200cc of blood at any given point increasing the oxygen saturation levels in one minute.
Inspira will get the support of GlobalLogic for the development of the ART control platform algorithm required for monitoring and managing quick rebalancing of the oxygen saturation levels of the patient. The algorithm will also activate and control proprietary technologies and data collected from advanced sensors that measure oxygen saturation, haemoglobin, blood temperature, and haematocrit levels, and blood flow and pressure. Inspira Technologies states that the ART can possibly reduce the need for mechanical ventilators for patients that are hypoxemic such as COVID patients. In addition, GlobalLogic will be leading the verification testing of the systems.
President & CEO, GlobalLogic, Shashank Samant, said: “Software plays an increasingly more crucial role in driving the overall efficacy of medical devices today. It also enhances the patient engagement with and medical staff’s use of such technologies. For nearly twenty years, we’ve worked with world-renowned medical device manufacturers as well as start-ups in today’s medtech innovation hotspots. We’re honored to have the opportunity to play such a pivotal role in bringing to market another disruptive technology, the ART. Particularly at such a critical time when there is a dire need for advanced treatment options.”
GlobalLogic has deep expertise focused around key medical device capabilities: data collection and analysis; device performance; and intuitive medical personnel and patient experiences. Regarding the ART, GlobalLogic contribution will assist Inspira Technologies to produce a digitally enhanced artificial lung and ensure medical staff is empowered with vital patient stats required to make it easy to monitor effectiveness and progress.
CEO, Inspira Technologies, Dagi Ben-Noon said: “It was imperative that we find a partner with both specialized medtech capabilities and the scale required to meet our design goals as we are dedicated to introducing to market a technology needed to fill the critical gap in the current days’ medical treatment options for patients with respiratory failure who keep deteriorating after treatment with non-invasive ventilation devices. Our decision to partner with GlobalLogic was driven by its proven ability in the medical device landscape and the capacity to meet aggressive time-to-market requirements with reliable solutions.”
ART is currently in development with the anticipated regulatory submission of its ART ECLS at the end of 2022.
